FGF21 and metabolic dysfunction-associated steatohepatitis: Efruxifermin has paved the way by establishingthe potential role of FGF21 in the treatment of MASH, with an effecton MASH resolution and fibrosis improvement after just 24 weeks inpatients with MASH with fibrosis score 2/3,43,49 leading to high expectations for the FGF21 drug class in MASH, aprogressive disease with no current treatment options.50 Efruxifermin, pegozafermin, BOS-580, and zalferminare currently being tested in phase 2 clinical MASH trials.